View Older Stories
-
Bristol-Myers/Celgene Deal Likely Kicks Off 'Big Year' In Biopharma M&A - RBC
-
RBC Capital Downgrades Celgene (CELG) to Sector Perform Following Acquisition
-
Pre-Open Movers 12/03: (TSRO) (GBT) (NBEV) Higher; (OCUL) (BLUE) (GSK) Lower (more...)
-
Celgene (CELG) Anti-CD47 Study Termination Seen Specific to AML/MDS - RBC
-
RBC Discusses Celgene (CELG) Going Private at $120/Share Post-Elon
-
Data Shows Funds Bailed On Celgene (CELG), Which Could Suggest a Rebound - RBC
-
Celgene (CELG) Weakness on Golumbeski Exit 'Unfounded' - RBC
-
FDA names drugmakers potentially acting to delay cheap generics
-
Vertex Pharma (VRTX), Alexion Pharma (ALXN) Least Impacted from Trump Drug Policies - RBC
-
RBC Capital Downgrades Celgene (CELG) to Outperform
-
Celgene (CELG) Revlimid Settlement Likely - RBC
-
RBC Explores a Possible LBO of Celgene (CELG)
-
Celgene (CELG) PT Lowered to $131 at RBC Capital; Sees Modest Ozan Delay
-
Celgene Corporation to Webcast at Upcoming Investor Conferences
-
Pre-Open Movers 01/22: (BIVV) (JUNO) (ARRY) Higher; (SANM) (TEVA) (TWTR) Lower (more...)
-
RBC Capital Starts Celgene (CELG) at Top Pick
-
Pre-Open Movers 07/06: (HSNI) (BGNE) (CYTX) Higher; (EGLT) (TAHO) (AZZ) Lower (more...)
-
Teva CEO exits in ongoing crisis of confidence at drugmaker
-
Pfizer boosts cancer drug roster with $14 billion Medivation deal
-
Biogen (BIIB) Could Be Worth $375-475/Share in a Takeover - RBC Capital's Yee
-
3 Key Takeaways as Medivation (MDVN) Enters Next Phase of Takeover Talks
-
Biotech Seen Grinding Higher, Says RBC Capital (IBB)
-
Celgene Corporation to Webcast at Upcoming Investor Conferences
-
Celgene's (CELG) Victory vs Hayman Group Removes Overhang, Says RBC
-
Celgene's (CELG) First IPR Not Relevant, Says RBC
-
Buyers Seem Like Deer-in-Headlights: RBC Capital; Analyst Comments on Biotech Rout
-
Analyst Touches on Read Through from Dismissal of Acorda (ACOR) IPR (BIIB) (CELG)
-
UPDATE: Celgene (NASDAQ: CELG) Price Target Raised to $150 at RBC; Analyst Discusses Bull/Bear Case (RCPT)
-
Pre-Open Stock Movers 06/30: (JUNO) (WSH) (PNR) Higher; (ETRM) (APOL) (SNE) Lower (more...)
-
RBC Capital Views Celgene (CELG), Juno (JUNO) Deal as Incremental Positve
-
Acorda (ACOR) IPR Patent Challenge Seen as Near-Term Overhang; RBC Maintains Outperform Rating
-
Celgene's (CELG) GED-0301 Receives Positive Feedback from Docs - RBC
-
RBC Capital Comments on Biotechs' Irish Tax Strategies; Gilead May See Modest EPS Impact (GILD) (AMGN)
-
Celgene (CELG): Buy Yesterday's Weakness, say RBC
-
Notable Analyst Rating Changes 05/29: (TWTR) (PANW) (DHI) Upgraded; (CELG) (DG) (PAGP) Downgraded
-
Notable Analyst Rating Changes 04/25: (CELG) (SYNA) (WFC) Upgraded; (KLAC) (LLTC) (CYTK) Downgraded
-
Pre-Open Stock Movers 4/2: (MNKD) (ENVI) (XLRN) Higher; (AGEN) (LQDT) (AGU) Lower (more...)
-
Notable Analyst Rating Changes 12/10: (CELG) (GERN) (ARIA) Upgraded; (DGX) (HME) (CHL) Downgraded
-
Notable 52-Week Highs and Lows of the Day 01/08: (PERI) (NCT) (CELG) High; (ALLT) (AU) Low
-
Notable Analyst Rating Changes 01/08: (CELG) (MGM) (LUV) Upgraded; (FIO) (DECK) (MYL) Downgraded
-
RBC Capital Upgrades Celgene (CELG) to Outperform
-
RBC Capital Downgrades Celgene (CELG) to Sector Perform
-
Notable Analyst Rating Changes 11/30: (LEAP) (AGU) (NAV) Upgraded; (NFLX) (SWN) (GLW) Downgraded
-
Notable 52-Week Highs and Lows of the Day 10/10: (ATVI) (CELG) (VRUS) High; (S) (ALTH) (BABY) Low
-
RBC Capital Upgrades Celgene (CELG) to Outperform
-
Notable Analyst Rating Changes 02/24: (CLS) (CHK) (HOS) (HRB) Upgraded; (LULU) (CELG) (FLR) (RHT) Downgraded
-
RBC Capital Upgrades Biogen (BIIB), Regeneron (REGN) to Outperform, Downgrades Celgene (CELG) to Sector Perform
-
Notable Analyst Rating Changes 9/2: TXT, CBE, SI, PAY, BBD Upgraded; ROK, GIS, HOLX, DHI, RYL, NVAX Downgraded
-
Notable Analyst Rating Changes 8/6: AXP, MGM, OWW, FCX, SPLS, DD Upgraded; CELG, FITB, OCNF, MELI, SHO Downgraded
-
Notable Analyst Rating Changes 2/4: RVBD, UPS, RSYS Upgraded; ADM, DIS, STI, WYNN Downgraded